ofloxacin has been researched along with Respiratory Syndrome, Acute, Severe in 5 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In treating SARS, ICWM was superior to the treatment with western medicine alone in aspects of improving clinical symptom, promoting recovery of immune function and absorption of lung inflammation, decreasing the dosage of hormone used and shortening the therapeutic course." | 2.71 | [Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine]. ( Jiao, Q; Wang, BG; Zhang, RL, 2003) |
| "We describe two patients with systemic lupus erythematosus (SLE) who presented with fever, systemic upset and pulmonary infiltrates between April and June, 2003." | 1.32 | Lupus pneumonitis or severe acute respiratory syndrome? ( Mok, CC; Ying, KY, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hynes-Gay, P | 1 |
| Bennett, J | 1 |
| Sarjoo-Devries, A | 1 |
| Jones, H | 1 |
| McGeer, A | 1 |
| Peiris, JS | 1 |
| Chu, CM | 1 |
| Cheng, VC | 1 |
| Chan, KS | 1 |
| Hung, IF | 1 |
| Poon, LL | 1 |
| Law, KI | 1 |
| Tang, BS | 1 |
| Hon, TY | 1 |
| Chan, CS | 1 |
| Chan, KH | 1 |
| Ng, JS | 1 |
| Zheng, BJ | 1 |
| Ng, WL | 1 |
| Lai, RW | 1 |
| Guan, Y | 1 |
| Yuen, KY | 1 |
| Zhang, RL | 1 |
| Jiao, Q | 1 |
| Wang, BG | 1 |
| Bian, YJ | 1 |
| Qi, WS | 1 |
| Song, QQ | 1 |
| Mok, CC | 1 |
| Ying, KY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Predictors for the Evolution of COVID-19 Related Interstitial Pneumonia by Transcriptomic and Seroproteomic Techniques[NCT04441502] | 204 participants (Actual) | Observational | 2020-03-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for ofloxacin and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
[Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine].
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Levofloxa | 2003 |
[Evaluation on effect of integrative medical treatment on quality of life of rehabilitation stage in 85 patients with SARS].
Topics: Adolescent; Adult; Aged; Convalescence; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hu | 2003 |
3 other studies available for ofloxacin and Respiratory Syndrome, Acute, Severe
| Article | Year |
|---|---|
Severe acute respiratory syndrome. The Mount Sinai experience.
Topics: Adult; Air Pressure; Anti-Infective Agents; Antiviral Agents; Canada; Female; Glucocorticoids; Human | 2003 |
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
Topics: Administration, Oral; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Disease Outbreaks; | 2003 |
Lupus pneumonitis or severe acute respiratory syndrome?
Topics: Adult; Antiviral Agents; China; Community-Acquired Infections; Diagnosis, Differential; Female; Huma | 2004 |